Libtayo was first approved in 2018, several years after Bristol-Myers Squibb and Merck & Co began to gain market share in many oncology indications with their rival PD-1 drugs Opdivo (nivolumab ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation. Given the current uncertainties and risks, I rate ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment ...

The potential to challenge incumbents Keytruda and Libtayo in the cSCC space is an exciting opportunity. The Checkpoint deal comes with a CVR related to approval of Unloxcyt in Europe, which may ...

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy, to ...